Berlin Partner works on economic growth and promotes businesses and innovations. Picture: ©?Uli Hölken / Campus Berlin-Buch GmbH

A well connected and effective infrastructure, a high density of research and development as well as close networking are of great value, not only to founders. Within the successful healthcare cluster Berlin-Brandenburg, these include numerous technology parks in the region. The parks offer optimal space including state of the art laboratories to start-up and grown-up companies.

Picture: © leon-nanodrugs GmbH

Manufacturing of COVID vaccines showed that large-scale production of lipid nanoparticles (LNPs) as a delivery vehicle for mRNA vaccines is already possible. As nanocarrier-based formulations became mainstream, however, insufficiencies in existing technologies for routine GMP manufacturing became apparent. LEON is committed to bridging these technology gaps through its unique FR-JET technology and innovative manufacturing equipment.

© Gerd Altmann - pixabay

Belgian fibrosis specialist Agomab Therapeutics NV has raised US$100m to advance development of its pipeline.

Picture: AAX Biotech

The Swedish start-up AAX Biotech welcomed Maria Lisa Knudsen as its new Managing Director at the end of September.

Astrocytes superimposed on a brain brighter cropped. © AstronauTx Ltd

Alzheimer’s specialist AstronauTx Ltd has closed a £48m Series A financing to create new treatments for Alzheimer’s diseas

SINO_KW41.jpg

Sino Biological, Inc., is pleased to announce the formal opening of its new Center for Bioprocessing (C4B) in Houston, Texas USA, adjacent to the world-renowned Texas Medical Center.

© BIOCOM AG

At the celebration of the 10th anniversary of the Bio-based Industry Consortium (BIC), the student team BioAroma was presented with the BISC-E 2023 award, which comes with €5000 in prize money.

© Olga Yastremska, New Africa, freepik

Researchers developed an innovative ear transplant method to treat microtia using tissue-engineered human skin and bioprinted cartilage.

Orakl Oncology's co-founders, Gustave Ronteix, Diane-Laure Pagès and Fanny Jaulin. © Orakl Oncology

Paris-based Orakl Oncology SA has raised €3m to develop its techbio platform for precision oncology.

Proprietary multi-omic data is the foundation of Indivumed's approach to precision medicine and drug development. Picture: ©Indivumed

Precision medicine tailors therapeutics to ­individual ­patients’ diseases, and is seen as the future of clinical practice. With significant time and ­financial investments ­being made in developing therapeutics, the ultimate success of ­patient-data driven precision ­therapies hinges on three main factors: the quality of the tissue samples, the associated molecular data, and the analysis used in their development.